Science.Online
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Area NEM :: Medical science :: Human medicine :: Nuclear medicine
 
F. Sudbrock, W. Eschner, M. Schmidt, T. Simon, B. Hero, H. Schicha

Dosimetry for therapeutic treatment of neuroblastoma by 131 I-mIBG

Keywords: Neuroblastom, mIBG-Therapie, Ganzkörperszintigraphie, SPECT, Dosimetrie, Energiedosis

AIM: Targeted radiotherapies using iodine-131 meta-iodobenzylguanidin have long been in use for treatment of stage IV neuroblastoma but reliable dosimetric data are scarce. METHOD: This work presents an approach to determine the whole body exposure and tumour doses delivered during therapy. Dosimetric data are reported and discussed for six treatments carried out according to the trial protocol NB2004 as it is in use in our study in the last two years. RESULTS: Whole body exposures are found to be in the range of 1.75 to 2.5 Gy whereas tumour doses vary between 15 and 55 Gy. CONCLUSION: The course of action prescribed by the trial protocol allows whole body exposure as well as tumour doses to be determined routinely.

Nuklearmedizin, Schattauer

Print ISSN: 0029-5566
Volume: 45, 01/2006
Pages: 254 - 261

Show full article (external site)

Show all available items of this journal